Scott Tagawa

It is widely considered that there is no single “Silver Bullet” that can be a widely received oncology treatment, ADCs and RLTs alike. With all therapies having their own specific drawbacks and therapeutic indices to take into account, a synergistic approach may be the best way to attack cancer from different biological angles.

Combination and multimodal approaches – pairing alpha and beta emitters or integrating RLT with PARP inhibitors or antibody-drug conjugates can enhance efficacy, reduce doses, and extend progression-free survival.

This session explores strategies to implement tandem and multimodal RLT approaches in the clinic, translating preclinical insights into safer, more effective patient care.

• Sequencing and synergy to optimize order and combination of therapies
• Patient selection using biomarkers, genomics, and receptor profiling
• Safety and efficacy balancing toxicity with therapeutic benefit
• Operational readiness ensuring supply chain and radiopharmacy reliability

–

Outcome – Design a clinical roadmap for various potential combination partners for RLTs.